About / the publisher
About Sermorelin Dr
An independent editorial broadsheet that reads the sermorelin literature and lays it out in plain, cited panels — what it is, what it is not, and how to read it.
What this site is
Sermorelin Dr is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin (GHRH(1-29)). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The approach is a broadsheet: take a compound surrounded by marketing and lay the actual studies out as plain, legible panels a non-specialist can read. Every quantitative claim is cited to the study that produced it, and every page distinguishes what the research established from what remains unproven.
What the 'Dr' in the name means — and does not
The "Dr" in Sermorelin Dr is editorial framing, not a clinical claim. It marks the measured, explanatory register of a health broadsheet that reads the literature carefully — the position this publisher occupies relative to the research. It does not mean the site is a doctor, a medical practice, or a telehealth service, and it does not offer treatment, consultation, diagnosis, or prescriptions.
We name no individual practitioner, claim no clinic or address, and refer to no "our doctors" or "our pharmacists," because there are none. The byline is the publication itself.
How we handle the evidence
We lead with findings and attribute them. When a body-composition or cognition result comes from the stabilized analog tesamorelin rather than native sermorelin, we say so rather than letting the family resemblance blur the source. When the data thin out — as they do for adult long-term safety — we leave the gap visible rather than filling it with optimism.
We also state the regulatory history precisely, because it is so often stated wrong: sermorelin was FDA-approved for pediatric growth hormone deficiency and withdrawn from the US market in 2008 for commercial reasons, not for safety or efficacy. Reporting that accurately is part of the editorial job.
What we do not do
We do not recommend doses, design protocols, or tell anyone what to take. We do not sell sermorelin or link to vendors. We do not present research-grade material as a medicine to self-administer. Where this site reports a studied dose, it is reported as a study parameter in a research population — never as guidance. Anyone considering a health decision should consult a qualified, licensed professional.